Elizabeth R. Jenny-Avital
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elizabeth R. Jenny-Avital has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Cathy Chuang
Department of Neurology, Jacobi Medical Center, Bronx, New York
1 shared publicationDavid K. Stein
Jacobi Medical Center, Albert Einstein College of Medicine, Division of Infectious Diseases, Bronx, New York
1 shared publicationMaria Abadi
Pathology, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York
1 shared publicationSara T. Beatrice
Bureau of Laboratories, Retrovirology and Immunobiology Division, New York City Department of Health, New York
1 shared publication
Latest Publications
- Open Access
- 15 May 2004
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 38 (10) , 1507-1508
Persistence of HIV Drug Resistance Mutations: More Clues from Clinical Observations
Sir—Gandhi et al. [1] describe the long persistence of HIV drug resistance mutations in a patient infected primarily with drug-resistant HIV and describe subseq
- 15 May 2004
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 38 (10) , 1507-1508
Open AccessPersistence of HIV Drug Resistance Mutations: More Clues from Clinical Observations
Sir—Gandhi et al. [1] describe the long persistence of HIV drug resistance mutations in a patient infected primarily with drug-resistant HIV and describe subseq
- Open Access
- 1 September 2003
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 37 (5) , 739
Human immunodeficiency virus and hepatitis C virus: which is the cart, and which is the horse?
SIR—The interesting findings by Martinez-Sierra et al. [1] are subject to alternative interpretations that challenge some of the authors' underlying suppositions. The authors' observation of more-prevalent cirrhosis among patients with CD4+ cell counts ⩽200 cells/mm3 than among patients with CD4+ cells counts >200 cells/mm3 at the time of diagnosis of HIV infection was interpreted as evidence that HIV-induced immunosuppression accelerated hepatitis C virus (HCV) disease. Alternatively, the severity of HCV-induced liver disease could have been the cause, rather than the result, of the accelerated decrease in CD4+ cell counts. The possibility that HCV infection contributed to CD4+ cell count decreases in parallel with the severity of liver disease should not be excluded, given that the analysis by Martinez-Sierra et al. [1] did not take into account factors known to be associated with lower CD4+ cell counts, such as the duration of HIV infection and virus load. The observation in the Swiss HIV Cohort Study [2] that increases in CD4+ cell counts were smaller among HCV-infected patients in whom HIV loads were sustained at undetectable levels by HAART than among HCV-uninfected patients with the same response to treatment is compatible with the premise that liver disease adversely affects CD4+ cell count.
- 1 September 2003
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 37 (5) , 739
Open AccessHuman immunodeficiency virus and hepatitis C virus: which is the cart, and which is the horse?
SIR—The interesting findings by Martinez-Sierra et al. [1] are subject to alternative interpretations that challenge some of the authors' underlying suppositions. The authors' observation of more-prevalent cirrhosis among patients with CD4+ cell counts ⩽200 cells/mm3 than among patients with CD4+ cells counts >200 cells/mm3 at the time of diagnosis of HIV infection was interpreted as evidence that HIV-induced immunosuppression accelerated hepatitis C virus (HCV) disease. Alternatively, the severity of HCV-induced liver disease could have been the cause, rather than the result, of the accelerated decrease in CD4+ cell counts. The possibility that HCV infection contributed to CD4+ cell count decreases in parallel with the severity of liver disease should not be excluded, given that the analysis by Martinez-Sierra et al. [1] did not take into account factors known to be associated with lower CD4+ cell counts, such as the duration of HIV infection and virus load. The observation in the Swiss HIV Cohort Study [2] that increases in CD4+ cell counts were smaller among HCV-infected patients in whom HIV loads were sustained at undetectable levels by HAART than among HCV-uninfected patients with the same response to treatment is compatible with the premise that liver disease adversely affects CD4+ cell count.
- 15 December 2002
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 35 (12) , e128-e133
Immune Reconstitution Cryptococcosis after Initiation of Successful Highly Active Antiretroviral Therapy
Five of 10 patients who commenced successful highly active antiretroviral therapy (HAART) for infection with human immunodeficiency virus type 1 (HIV-1) concurrent with or soon after a diagnosis of cryptococcal infection experienced clinical events characterized by sterile inflammation. Two patients developed aseptic meningitis with elevated intracranial pressure, 1 developed intrathoracic lyphadenopathy with hypercalcemia, 1 developed cavitary pneumonia at the site of a cryptococcal nodule, and 1 developed a supraclavicular abscess. These events occurred 2–11 months after initiation of HAART. For 3 patients, biopsy demonstrated findings atypical for acquired immunodeficiency syndrome—associated cryptococcosis. Results of fungal cultures were negative for all 5 patients, and cryptococcal antigen levels had declined markedly in 4 patients. The timing and clinical features of and biopsy findings for these cases of cryptococcosis suggest the existence of a paradoxical reaction to Cryptococcus infection that occurs in the context of HIV immune restoration.
- 15 December 2002
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 35 (12) , e128-e133
Immune Reconstitution Cryptococcosis after Initiation of Successful Highly Active Antiretroviral Therapy
Five of 10 patients who commenced successful highly active antiretroviral therapy (HAART) for infection with human immunodeficiency virus type 1 (HIV-1) concurrent with or soon after a diagnosis of cryptococcal infection experienced clinical events characterized by sterile inflammation. Two patients developed aseptic meningitis with elevated intracranial pressure, 1 developed intrathoracic lyphadenopathy with hypercalcemia, 1 developed cavitary pneumonia at the site of a cryptococcal nodule, and 1 developed a supraclavicular abscess. These events occurred 2–11 months after initiation of HAART. For 3 patients, biopsy demonstrated findings atypical for acquired immunodeficiency syndrome—associated cryptococcosis. Results of fungal cultures were negative for all 5 patients, and cryptococcal antigen levels had declined markedly in 4 patients. The timing and clinical features of and biopsy findings for these cases of cryptococcosis suggest the existence of a paradoxical reaction to Cryptococcus infection that occurs in the context of HIV immune restoration.
- 15 December 2002
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 35 (12) , 1576-1577
Clinical manifestations of discordance between cerebrospinal fluid and plasma HIV-1 loads.
- 15 December 2002
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 35 (12) , 1576-1577
Clinical manifestations of discordance between cerebrospinal fluid and plasma HIV-1 loads.
- 27 June 2002
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 346 (26) , 2088-2089
Bisphosphonates and Osteoporosis
The prospect of a quick fix for the problem of postmenopausal osteoporosis by means of intermittent administration of intravenous bisphosphonate is exciting. Reid et al. (Feb. 28 issue)1 report that bone mineral density was increased for up to one year after intermittent intravenous therapy with zoledronic acid. The authors do not discuss the rate of nonvertebral fractures, which, if anything, was higher in the treated group than in the placebo group. The authors do point out that all the women in their study had base-line bone-mineral-density values that were high enough that therapy would not have been recommended, according to the current guidelines. Although treatment may have salutary effects on surrogate markers of bone turnover and on bone density, a reduction in the rate of fracture is the gold standard of efficacy. Thus, it seems surprising that the authors do not mention the observed fracture rates in their discussion. Specifically, were the fractures that occurred in bones that were less favorably affected by the treatment (e.g., the radius) or were they hip fractures?
- 27 June 2002
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 346 (26) , 2088-2089
Bisphosphonates and Osteoporosis
The prospect of a quick fix for the problem of postmenopausal osteoporosis by means of intermittent administration of intravenous bisphosphonate is exciting. Reid et al. (Feb. 28 issue)1 report that bone mineral density was increased for up to one year after intermittent intravenous therapy with zoledronic acid. The authors do not discuss the rate of nonvertebral fractures, which, if anything, was higher in the treated group than in the placebo group. The authors do point out that all the women in their study had base-line bone-mineral-density values that were high enough that therapy would not have been recommended, according to the current guidelines. Although treatment may have salutary effects on surrogate markers of bone turnover and on bone density, a reduction in the rate of fracture is the gold standard of efficacy. Thus, it seems surprising that the authors do not mention the observed fracture rates in their discussion. Specifically, were the fractures that occurred in bones that were less favorably affected by the treatment (e.g., the radius) or were they hip fractures?
- Open Access
- 15 April 2001
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 32 (8) , 1227-1230
Erroneously Low or Undetectable Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid Load, Determined by Polymerase Chain Reaction, in West African and American Patients with Non-B Subtype HIV-1 Infection
The polymerase chain reaction (PCR) assay for plasma human immunodeficiency virus type 1 (HIV-1) ribonucleic acid (RNA) inadequately quantitates viru
- 15 April 2001
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 32 (8) , 1227-1230
Open AccessErroneously Low or Undetectable Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid Load, Determined by Polymerase Chain Reaction, in West African and American Patients with Non-B Subtype HIV-1 Infection
The polymerase chain reaction (PCR) assay for plasma human immunodeficiency virus type 1 (HIV-1) ribonucleic acid (RNA) inadequately quantitates viru
- Open Access
- 15 January 2001
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 32 (2) , 322-323
Protease Inhibitors and Rifabutin: Isn't the Jury Still Out?
Sir—The attempt by Narita et al. [1] to delineate the pharmacokinetic interactions between HIV type 1 protease inhibitors (PIs) and rifabutin administered inter
- 15 January 2001
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 32 (2) , 322-323
Open AccessProtease Inhibitors and Rifabutin: Isn't the Jury Still Out?
Sir—The attempt by Narita et al. [1] to delineate the pharmacokinetic interactions between HIV type 1 protease inhibitors (PIs) and rifabutin administered inter
- Open Access
- 1 February 2000
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 30 (2) , 409-410
Does Hepatitis C Virus Really Have No Effect on Survival in Cases of Infection with Human Immunodeficiency Virus?
Sir—Staples et al. [1] found no deleterious effect due to hepatitis C virus (HCV) coinfection on survival in a group of 350 HIV-infected (115 HCV-positive and 235 HCV-negative) patients whose HCV status had been determined for unspecified clinical indications. The patients were part of a cohort of >1800 patients followed at the Atlanta Veterans Affairs Medical Center, whose HCV antibody status was not uniformly ascertained.
- 1 February 2000
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 30 (2) , 409-410
Open AccessDoes Hepatitis C Virus Really Have No Effect on Survival in Cases of Infection with Human Immunodeficiency Virus?
Sir—Staples et al. [1] found no deleterious effect due to hepatitis C virus (HCV) coinfection on survival in a group of 350 HIV-infected (115 HCV-positive and 235 HCV-negative) patients whose HCV status had been determined for unspecified clinical indications. The patients were part of a cohort of >1800 patients followed at the Atlanta Veterans Affairs Medical Center, whose HCV antibody status was not uniformly ascertained.